Princeton, N.J.-based Regentis Biomaterials has increased the number of sites in its clinical trial of the GelrinC tissue regeneration implant.
Regentis is adding 30 new patients at 12 sites in Germany, Belgium, Poland, the Netherlands and Israel. The expansion is more than doubling the original scope of the study, bringing the total number of treated patients to 53, according to the release.
The implant is designed to grow hyaline-like cartilage in damaged knees through filling the lesions with acellular material. GelrinC is an off-the-shelf product for patients with traumatic knee injuries.
More Articles on Devices:
Medical Device Quality is Subject of New Healthcare Partnership
Precision Spine Names Tony Dimun Board Member, Special Adviser
IlluminOss Medical Names Dirk Kuyper President, CEO
The implant is designed to grow hyaline-like cartilage in damaged knees through filling the lesions with acellular material. GelrinC is an off-the-shelf product for patients with traumatic knee injuries.
More Articles on Devices:
Medical Device Quality is Subject of New Healthcare Partnership
Precision Spine Names Tony Dimun Board Member, Special Adviser
IlluminOss Medical Names Dirk Kuyper President, CEO